Eva Martinez‐Balibrea

Author

Also Known As

E Martinez-Balibrea, E. Martinez-Balibrea, E. Martínez-Balibrea, Eva Martinez-Balibrea, Eva Martinez‐Balibrea, Eva Martínez-Balibrea, Eva Martínez-Balibrea

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Institut Català d'Oncologia Hospital Universitari Germans Trias i Pujol Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Institut d'Investigació Biomédica de Bellvitge Universitat de Barcelona

About

Eva Martinez‐Balibrea is an author at Institut Català d'Oncologia specializing in oncology, medicine, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	486
2	Cell Biology	5	5	195
3	Pathology	5	5	295
4	Engineering	1	1	64
5	Health Sciences	1	1	14

Eva Martinez‐Balibrea

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway Vicenç Ruiz de Porras, Sara Bystrup, Anna Martínez‐Cardús, Scientific Reports	2016	131
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect Paula López-Serra, Miguel Marcilla, Alberto Villanueva, Nature Communications	2014	113
Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer Cátia Moutinho, Anna Martínez‐Cardús, Cristina Santos, JNCI Journal of the National Cancer Institute	2013	96
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús, British Journal of Cancer Tyms Genetic VariantsOncologyOncogenic AgentMedicineFluorouracil Combination Therapy	2010	88
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer Jordi Codony‐Servat, Míriam Cuatrecasas, Elena Asensio, British Journal of Cancer	2017	76
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer Eva Martinez‐Balibrea, Albert Abad, Enrique Aranda, European Journal of Cancer Pharmacogenetic ApproachMedicinePharmacologyColorectal CancerPharmacotherapy	2008	72
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Eva Musulén, International Journal of Cancer	2009	70
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells Carmen Plasencia, Eva Martinez‐Balibrea, Anna Martínez‐Cardús, International Journal of Oncology PathologyCancer BiologyTumor BiologyOxidative StressPlatinum Resistance	2006	68
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism Albert Font, José Miguel Sánchez, Miquel Tarón, Investigational New Drugs UrologyOncogenic AgentMedicineHuman PolymorphismWeekly Regimen	2003	67
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines Eva Martinez‐Balibrea, Carmen Plasencia, Alba Ginés, Molecular Cancer Therapeutics	2009	66

Page 1